Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial
Alessandro Gronchi(Fondazione IRCCS Istituto Nazionale dei Tumori), Paolo G. Casali(Fondazione IRCCS Istituto Nazionale dei Tumori), Domenico Franco Merlo, Javier Martín‐Broto(Hospital Universitario Fundación Jiménez Díaz), Vittorio Quagliuolo(Humanitas University), Rita De Sanctis(Humanitas University), Angelo Paolo Dei Tos(University of Padua), Paolo Bruzzi(Alleanza Contro il Cancro), Virginia Ferraresi(Cancer Institute (WIA)), Iwona Ługowska(The Maria Sklodowska-Curie National Research Institute of Oncology), Jean‐Yves Blay(Université Claude Bernard Lyon 1), Giovanni Grignani(Candiolo Cancer Institute), Valeria Fontana(Ospedale Policlinico San Martino), Silvia Stacchiotti(Fondazione IRCCS Istituto Nazionale dei Tumori), Elena Palassini(Fondazione IRCCS Istituto Nazionale dei Tumori), Oscar Tendero(Hospital Universitario Son Espases), Sílvia Bagué(Universitat Autònoma de Barcelona), Carlo Morosi(Fondazione IRCCS Istituto Nazionale dei Tumori), Emanuela Palmerini(Istituto Ortopedico Rizzoli), Umberto Basso(Istituto Oncologico Veneto), Piero Picci(Istituto Ortopedico Rizzoli), Antonio López–Pousa(Hospital de Sant Pau), Davide María Donati(University of Modena and Reggio Emilia), Stefano Ferrari(University of Bergamo), Emanuela Marchesi(Istituto Ortopedico Rizzoli), J.M. Coindre(Institut Bergonié), Robert Díaz Beveridge(Hospital Universitari i Politècnic La Fe)
Cited by 493
Related Papers
Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial
|The Lancet|2012|2.1k
Vemurafenib in Multiple Nonmelanoma Cancers with <i>BRAF</i> V600 Mutations
|New England Journal of Medicine|2015|1.7k
Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2018|1.6k
Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy
|New England Journal of Medicine|2016|1.3k